|1.||Yamada, Y: 1 article (01/2000)|
|2.||Sato, K: 1 article (01/2000)|
|3.||Toko, T: 1 article (01/2000)|
|4.||Fujioka, A: 1 article (01/2000)|
|5.||Shibata, J: 1 article (01/2000)|
|6.||Lykkesfeldt, A E: 1 article (01/2000)|
|7.||Hashimoto, A: 1 article (01/2000)|
|8.||Saito, H: 1 article (01/2000)|
|9.||Wierzba, K: 1 article (01/2000)|
03/01/1990 - "These experiments showed that TAT-59 was more effective in lower doses than TAM, even against the tumors with low ER content."
12/01/1992 - "These findings suggest that TAT-59 might merit use in clinical trials with breast cancers."
01/01/1995 - "These results suggest that the superior antiestrogenic activity of TAT-59 compared to TAM was either due to its higher penetration into tumor tissue or to the stronger antiestrogenic activity of its metabolites."
01/01/1994 - "The most clear decrease in tumor growth was shown in the TAT-59 alone group, although it was not dramatic. "
03/01/1990 - "Especially in the tumors with low ER levels (10-20 fmol/mg protein), TAT-59 showed a significantly stronger inhibitory effect than TAM. "
|2.||Breast Neoplasms (Breast Cancer)
05/01/1998 - "[Early phase II study of TAT-59 in patients with advanced or recurrent breast cancer--a multicenter dose finding study]."
06/01/1998 - "In conclusion, TAT-59 was showed comparable efficacy and safety with TAM in ER-positive or ER-unknown patients with advanced or recurrent breast cancer."
05/01/1998 - "TAT-59 inhibited the growth of tamoxifen-resistant breast cancer cell lines, R-27 and FST-1, but not tamoxifen, suggesting the possible efficacy of TAT-59 for tamoxifen-refractory patients. "
06/01/1998 - "[Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)]."
05/01/1998 - "A dose finding early phase II study of TAT-59, a new triphenylethylene derivative, was performed in patients with advanced or recurrent breast cancer. "
05/01/1998 - "TAT-59 suppressed the growth of mammary carcinoma, MCF-7 and Br-10, xenografted into nude mouse at a dose of 5 mg/kg/day, which is equivalent to 20 mg/body of daily dose to the patients. "
01/01/1995 - "Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma."
|5.||Weight Loss (Weight Reduction)
|3.||Estrogen Receptor Modulators (Antiestrogen)
|6.||2- (4- (1- (4- hydroxyphenyl)- 2- (4- isopropylphenyl)- 1- butenyl)phenoxy)- N,N- dimethylethylamine
|1.||Heterologous Transplantation (Xenotransplantation)